Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

Presentation TCT 2019

PICCOLETO II: 6-Month Clinical and Angiographic Findings From a Randomized Trial of Drug-Coated Balloons vs. Drug-Eluting Stents for Treatment of Small Vessel Coronary Artery Disease

Presenter: Bernardo Cortese

September 27, 2019

Presentation TCT 2019

TOBA III: 1-Year Outcomes From a Single-Arm Study of Focal Dissection Repair After Drug-Coated Balloon Angioplasty of Superficial Femoral And Proximal Popliteal Arteries

Presenter: Marianne Brodmann

September 27, 2019

Presentation TCT 2019

LUTONIX BTK Diabetes: Outcomes From a Randomized Trial of a Drug-Coated Balloon vs. Standard Angioplasty in Diabetic Patients With Below-the-Knee Disease

Presenter: Marianne Brodmann

September 27, 2019

Presentation TCT 2019

Perspective: The Case for Ongoing Use of Drug-Eluting Technologies for PAD

Presenter: William Gray

September 27, 2019

Presentation TCT 2019

Perspective: The Case Against Ongoing Use of Drug-Eluting Technologies for PAD

Presenter: Konstantinos Katsanos

September 27, 2019

Presentation TCT 2019

TCT 64: Intravascular Molecular-Structural Imaging of Arterial Permeability and Vascular Injury In Vivo: Implications for Drug-Coated Balloon Efficacy

Presenter: Mazen Albaghdadi

September 25, 2019

Presentation TCT 2019

DCBs for Infrainguinal Arterial Occlusive Disease With or Without Adjunctive Techniques Are Better Than Primary Stenting

Presenter: Brian DeRubertis

September 25, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

Advertisement

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

PICCOLETO II: 6-Month Clinical and Angiographic Findings From a Randomized Trial of Drug-Coated Balloons vs. Drug-Eluting Stents for Treatment of Small Vessel Coronary Artery Disease

TOBA III: 1-Year Outcomes From a Single-Arm Study of Focal Dissection Repair After Drug-Coated Balloon Angioplasty of Superficial Femoral And Proximal Popliteal Arteries

LUTONIX BTK Diabetes: Outcomes From a Randomized Trial of a Drug-Coated Balloon vs. Standard Angioplasty in Diabetic Patients With Below-the-Knee Disease

Perspective: The Case for Ongoing Use of Drug-Eluting Technologies for PAD

Perspective: The Case Against Ongoing Use of Drug-Eluting Technologies for PAD

TCT 64: Intravascular Molecular-Structural Imaging of Arterial Permeability and Vascular Injury In Vivo: Implications for Drug-Coated Balloon Efficacy

DCBs for Infrainguinal Arterial Occlusive Disease With or Without Adjunctive Techniques Are Better Than Primary Stenting

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content